ALNYLAM PHARMACEUTICALS, INC.

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer

Filing 1st Quarter - Report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Expenses

$430,000.00

What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

Massachusetts

Official filing document

Lobbyists on this filing 1

CURTIS RHYNE

Previously held: Rep. Virginia Foxx (2008-2009), House Republican Study Committee (2009-2014), Rep. Richard Hudson (2014-2017), Rep. George Holding (2017-2020)

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 2

HR 4993
Joe Fiandra Access to Home Infusion Act of 2025
HR 1672
Maintaining Investments in New Innovation Act

Lobbying activity 3

Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act; issues related to MFN drig pricing

Trade (domestic/foreign)

Issues relating to supply chain tariffs

Pharmacy

Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94); issues related to drug pricing; FY2026 Labor HHS appropriations, issues related to genetically targeted technologies; HR1672, Maintaining Investments in New Innovation Act.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.